1.Adult Male or Female patients aged 18 to 45 years (both Inclusive) <br/ > <br/ >2. Patients with COVID-19 disease confirmed by RT-PCR at screening. The latest RT-PCR test result should be within 3 days prior to randomization/ first dose of investigational product <br/ >3. Patients with a COVID-19 disease whose first symptom onset is â?¤ 7 days from first dose of investigational product <br/ >4.Patients requiring hospitalization for treatment of COVID-19 infection and who fulfil a score of either 4 or 5 on the WHO 10-point Progression Scale at randomization/prior to administration of first dose of IP <br/ >5.Oxygen saturation (SPO2) between 90% to 93% (both inclusive) on room air at randomization/ prior to administration of first dose of IP <br/ >6.Capable and willing to provide written informed consent prior to the performance of any study- specific procedures.

1.Adult Male or Female patients aged 18 to 45 years (both Inclusive) <br/ > <br/ >2. Patients with COVID-19 disease confirmed by RT-PCR at screening. The latest RT-PCR test result should be within 3 days prior to randomization/ first dose of investigational product <br/ >3. Patients with a COVID-19 disease whose first symptom onset is â?¤ 7 days from first dose of investigational product <br/ >4.Patients requiring hospitalization for treatment of COVID-19 infection and who fulfil a score of either 4 or 5 on the WHO 10-point Progression Scale at randomization/prior to administration of first dose of IP <br/ >5.Oxygen saturation (SPO2) between 90% to 93% (both inclusive) on room air at randomization/ prior to administration of first dose of IP <br/ >6.Capable and willing to provide written informed consent prior to the performance of any study- specific procedures.

1.Adult Male or Female patients aged 18 to 45 years (both Inclusive) <br/ > <br/ >2. Patients with COVID-19 disease confirmed by RT-PCR at screening. The latest RT-PCR test result should be within 3 days prior to randomization/ first dose of investigational product <br/ >3. Patients with a COVID-19 disease whose first symptom onset is â?¤ 7 days from first dose of investigational product <br/ >4.Patients requiring hospitalization for treatment of COVID-19 infection and who fulfil a score of either 4 or 5 on the WHO 10-point Progression Scale at randomization/prior to administration of first dose of IP <br/ >5.Oxygen saturation (SPO2) between 90% to 93% (both inclusive) on room air at randomization/ prior to administration of first dose of IP <br/ >6.Capable and willing to provide written informed consent prior to the performance of any study- specific procedures.

1.Adult Male or Female patients aged 18 to 45 years (both Inclusive) <br/ > <br/ >2. Patients with COVID-19 disease confirmed by RT-PCR at screening. The latest RT-PCR test result should be within 3 days prior to randomization/ first dose of investigational product <br/ >3. Patients with a COVID-19 disease whose first symptom onset is â?¤ 7 days from first dose of investigational product <br/ >4.Patients requiring hospitalization for treatment of COVID-19 infection and who fulfil a score of either 4 or 5 on the WHO 10-point Progression Scale at randomization/prior to administration of first dose of IP <br/ >5.Oxygen saturation (SPO2) between 90% to 93% (both inclusive) on room air at randomization/ prior to administration of first dose of IP <br/ >6.Capable and willing to provide written informed consent prior to the performance of any study- specific procedures.